Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Emerisque
Statement By Emerisque Re: Stalking Horse Selection
June 21st, 2009
Emerisque and its partner SKNL North America ("the Purchasers") are pleased that the United States Bankruptcy Court in the District of Chicago has today approved the motion by Hartmarx Corporation selecting them as the stalking horse bidder. As a result of last minute negotiations over the weekend, the Purchasers and the Company, supported by its lenders, have agreed to a total transaction value of $128.4 million for the acquisition of substantially all of the assets of Hartmarx Corporation and the assumption of certain liabilities. The Emerisque-SKNL offer was the only bid that committed to keeping the business whole and operating it as a going...
Source: Pharma Investments, Ventures & Law Weekly (2009-06-21)
|
